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Background: About 20% of patients with a first ischaemic stroke will experience a new vascular event within
the first year. The atherosclerotic burden, an indicator of the extension of atherosclerosis in a patient, has been
associated with the risk of new cardiovascular events in the general population. However, no predictive models
reliably identify groups at a high risk of recurrence. The ARTICO study prospectively analysed the predictive value
for the risk of recurrence of specific atherosclerotic markers.
Methods: The multicentre ARTICO study included 620 consecutive independent patients older than 60 years
suffering from a first non-cardioembolic stroke. We analysed classical stroke risk factors; duplex study of supraaortic
trunk including intima-media thickness (IMT) measurement; quantification of internal carotid (ICA) stenosis; number,
morphology and surface characteristics of carotid plaques; ankle brachial index (ABI); and the presence of
microalbuminuria. Patients were followed up at 6 and 12 months after inclusion. The primary end-point was
death or major cardiovascular events.
Results: Any vascular event or death at 12 months occurred in 78 (13.8%) patients. In 40 (7.1%) of these the vascular
event was a stroke recurrence. Weight, history of diabetes mellitus, history of symptomatic PAD, ABI <0.9 and
significant ICA stenosis (>50%) were associated with a higher risk of vascular events on follow-up in the bivariate
analysis.
In the final Cox regression analysis, body mass index (BMI), systolic blood pressure, history of diabetes mellitus,
symptomatic PAD (HR, 2.76; 95% CI, 1.10–6.95; p=0.03), and particularly patients with both ICA stenosis >50% and
PAD (HR 4.52; 95% CI, 2.14-9.53; p<0.001) were independently associated with an increased risk of vascular events.
Neither isolated ICA stenosis >50% nor isolated abnormal ABI remained associated with an increased risk of
recurrence in comparison with the whole population.
Conclusions: Symptomatic PAD identifies a high risk group of vascular recurrence after a first non-cardioembolic
stroke. The associated increased risk was particularly high in patients with both ICA stenosis and either symptomatic
or asymptomatic PAD. Neither asymptomatic PAD alone nor isolated ICA stenosis >50% were associated with an
increased risk of recurrence in this particularly high-risk group of non-cardioembolic stroke.
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Atherothrombosis is the first cause of death and disabil-
ity in industrialized countries. Both asymptomatic and
symptomatic atherosclerotic disease frequently coexist in
more than one of the typical territories (coronary artery
disease, cerebrovascular disease and peripheral arterial
disease) and share similar stroke risk factors [1]. The
atherosclerotic burden, an indicator of the extension of
atherosclerosis in a patient, has been associated with the
risk of new cardiovascular events in the general popula-
tion [2,3]. Several studies have associated the presence
of both asymptomatic and symptomatic atherosclerotic
disease with the risk of cardiovascular events [4-10].
However, these studies have tended to be in the general
population and often mainly of elderly patients. Few
studies have been aimed at patients who have suffered a
first ischaemic stroke [11-18]. In the case of the specific
sub-group of non-cardioembolic strokes, the evaluation
of the atherosclerotic burden could well be of great
interest as about 20-40% of these patients will suffer recur-
rence within the first five years [19] despite the currently
most appropriate secondary stroke prevention measures
being taken. Although several clinical, radiological, ultra-
sonographic [13-18,20] and molecular markers have been
identified as having predictive value for stroke recurrence,
no predictive model reliably identifies patients at a high
risk of a new vascular event. The management of non-
cardioembolic stroke is currently almost identical in all pa-
tients. However, the identification of those who are at
greater risk of vascular event recurrence should be a major
objective with a view to possibly following a more intensive
treatment in these patients [21,22].
The ARTICO study aimed to prospectively analyse the
association of several markers of atherosclerosis with the




The ARTICO study is a prospective, multicentre, obser-
vational study undertaken in 42 Spanish neurology de-
partments (see Additional file 1) [23]. ARTICO included
independent patients older than 60 years with a recent
non-cardioembolic ischaemic stroke according to SSS-
TOAST criteria [24]. In order to avoid unstable neuro-
logical patients with a risk of early neurological deterior-
ation or death due to the index stroke, patients were
included between day 5 and day 90. All patients were eval-
uated by a neurologist before inclusion in the study to
confirm the nature of the event under a standardised
aetiological protocol, including a complete personal and
family medical history of vascular risk factors as well as
clinical examination including height, weight, waist cir-
cumference, and arterial blood pressure. Routine bloodand coagulation tests, and brain computed tomography or
magnetic resonance were performed on all patients.
As markers of atherosclerotic disease, duplex study of
the supraaortic trunks including intima-media thickness
(IMT) measurement; quantification of internal carotid
stenosis; number, morphology and surface characteristics
of carotid plaques; ankle brachial index (ABI); and the
presence of microalbuminuria were performed at study
inclusion.
Patients were followed up at 6 and 12 months after in-
clusion. Vascular events, including stroke recurrence, is-
chaemic heart disease, symptomatic peripheral arterial
disease (PAD), vascular surgery and death of vascular or
non-vascular origin were recorded. Symptomatic PAD
was only accepted as an outcome event where a patient
did not have a previous history of this disease or where
a patient with a previous history required peripheral
vascular surgery due to clear worsening. The modified
Rankin scale (mRankin) was evaluated at discharge and
at 6 and 12 month visits. Additional investigations were
left at the discretion of the investigator in charge of the
patient. The primary end-point of the ARTICO study
was death or major vascular events.Atherothrombotic marker protocol
ABI measurement was performed using an 8 MHz probe
and the same Doppler model (ES-100X) in all centres
after a consensus meeting. Doppler systolic blood pres-
sure at the right and left sides in both brachial arteries
as well as both the dorsalis pedis artery and posterior
tibial arteries were recorded with patients at rest for at
least 5 minutes in the supine position [25,26]. The ABI
was calculated centrally. Asymptomatic PAD was de-
fined as ABI ≤0.9 whereas PAD was considered to be
symptomatic when a history of walking impairment,
intermittent claudication, ischaemic rest pain, and/or
non-healing wounds was present [25].
Colour-duplex study of the supraaortic trunks was
performed on all patients. Carotid or intracranial artery
stenosis was quantified using established haemodynamic
criteria by echo-Doppler ultrasonography [27-30]. Each
neurosonology department used their own standardised
values or, in their absence, values validated in the litera-
ture. Plaques were classified by echogenicity and surface
morphology in accordance with consensus criteria [31].
IMT was measured on a still image during diastole in
both common carotid arteries (CCA) at the far wall and
at least 1 cm below the bifurcation on a 1 cm plaque-
free segment. The highest of 6 CCA measurements was
taken as the final IMT. In order to differentiate plaques
from just increased IMT, a plaque was defined as focal
thickening of ≥1.5 mm or either >0.5 mm or >50% of
the surrounding IMT [31,32].
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boratory methodology in accordance with the American
Diabetes Association and the National Kidney Foundation
recommendations using either the 24 hour albumin/
creatinine index or the nephelometric and Jaffe methods
[33,34]. An albumin-to-creatinine ratio of <30 mg/g of
creatinine was considered to be normal and albuminuria
was considered to be present when the albumin-to-
creatinine ratio was ≥30 mg/g of creatinine. The microal-
buminuric range was defined as an albumin-to-creatinine
ratio of between 30 and 300 mg/day of creatinine whereas
an albumin-to-creatinine ratio >300 mg/day was indicative
of macroalbuminuria.
The study was approved by the ethical committee of
each participating centre and informed consent was ob-
tained from patients or relatives (Additional file 2).
Statistical analysis
Proportions between groups were compared with the
chi-square test. Continuous variables were expressed as
mean +/− SD or median and quartiles and were com-
pared by the Student t test or the Mann–Whitney test,
as appropriate.
Overall survival was defined as the time (in days) be-
tween the date of the index stroke and the first recurrence.
Covariates that were of known clinical interest or that
were identified as significant (p < 0.05, Log-Rank test) in
the Kaplan-Meyer analysis were selected for multivariate
analysis, which was performed using Cox’s proportional
hazard models. Multicollinearity between predictors and
specifically of different atherosclerotic markers in the
final Cox model was assessed. The models were fitted in
a customized way by means of the ENTER method. Re-
sults were expressed as adjusted hazard ratios with the
corresponding 95% confidence intervals.
All analyses were performed with the SPSS statistical
package.
Results
Six-hundred and twenty independent patients older than
60 years suffering from a first non-cardioembolic stroke
were included in the study. The median time from stroke
onset to inclusion was 9 [6-20] days. Fifty-nine patients
(9.5%) were excluded from the analysis as they were lost
to follow-up.
The presence of classical stroke risk factors was similar
to other series. The frequency of probable and possible
atherothrombotic, small vessel disease and cryptogenic
stroke subtypes was 16.9%, 43.4%, 20.7%, and 19.1%.
Symptomatic PAD was present in 9.1% of patients
whereas ABI ≤0.9 was present in 28.6%. ICA stenosis
>50% was detected in 19.7% and plaques in 72.7%
(29.4% anechoic/hypoechoic). Mean and standard devi-
ation of IMT was 0.92 (0.39). Microalbuminuria waspresent in 21.9% and central obesity in 52.4% of patients
(40.1% in men and 80.4% in women).
Patients were followed up at 6 and 12 months after in-
clusion. Any vascular event or death occurred in 78
(13.8%) patients. In 40 (7.1%) of these the vascular event
was a recurrent stroke. In the bivariate analysis, few differ-
ences were detected in the prevalence of classical vascular
stroke risk factors. Weight, history of diabetes mellitus,
history of symptomatic PAD and hypoglycaemic treatment
before index stroke were associated in the bivariate ana-
lysis with higher risk of vascular events on follow-up
(Table 1). Table 2 shows the atherosclerotic markers ana-
lysed in patients with and without vascular events during
follow-up. There were significant differences between the
two groups in both abnormal ABI and symptomatic PAD.
In ultrasonographic study, ipsilateral significant ICA sten-
osis (>50%) was more frequent in the group that would
suffer further vascular events. However, no differences
were found in the plaque characteristics, the presence of
microalbuminuria or in IMT. When the different potential
combinations of PAD and ICA were analysed, only pa-
tients with both PAD and ICA stenosis were found to
have an increased risk of vascular events (Table 3).
In the final Cox regression analysis, BMI, systolic
blood pressure, history of diabetes mellitus, symptomatic
PAD (HR, 2.75; 95% CI, 1.10–6.88; p = 0.03) and the as-
sociation of ICA stenosis with both abnormal ABI (HR,
4.39; 95% CI, 2.09-9.23;p < 0.001) and symptomatic PAD
with ICA stenosis (HR, 3.72; 95% CI, 1.39-9.91; p =
0.009) remained independently associated with an in-
creased risk of vascular events (Table 3). Neither isolated
ICA stenosis >50% nor isolated abnormal ABI and IMT
were associated with an increased risk of recurrence in
comparison with the whole population.
Discussion
Patients with atherothrombosis or several risk factors for
this disease have been found to have relatively high rates
of cardiovascular events [1-10]. Given that atheroscler-
osis is a systemic condition, the vascular event can occur
in the same vascular territory or, as is frequently the case
in stroke patients, in a different one [2,35]. This in-
creased risk is associated both with symptomatic and
asymptomatic atherosclerosis. Although there is a well-
known strong association between abnormal ABI and in-
creased risk of severe vascular events, this association
has mainly been analysed in population-based studies,
often in asymptomatic patients [21,36-43] with little data
about the potential relevance of ABI as a predictor of
new vascular events in symptomatic patients, and par-
ticularly in those with previous atherothrombotic stroke
(non-cardioembolic). Few studies have analysed the rele-
vance of ABI [11-16] or IMT [17,18] as predictors of re-
currence in patients with a previous stroke and none has
Table 1 Classical factors associated with new vascular







Male, % 77.6 67.0 0.15
Age 72.6 (8.4) 71.1 (7.2) 0.31
Weight 78.8 (14.3) 74.8 (12.1) 0.01
Height 165.4 (7.5) 164.0 (8.0) 0.17
Body mass index 28.8 (4.7) 27.8 (4.3) 0.09
Waist circumference 101.0 (14.9) 100.1 (12.9) 0.22
Systolic blood pressure 162.4 (25.4) 152.4 (26.5) 0.06
Diastolic blood pressure 85.2 (13.3) 82.3 (13.5) 0.10
Familiar history of cardiovascular
disease
Stroke, % 23.1 18.1 0.52
Ischaemic CHD, % 11.5 16.3 0.31
Sudden death, % 5.1 3.3 0.50
Personal history
Alcohol intake, % (>40gr/day) 10.4 5.0 0.07
Active smoker, % 18.4 18.1 0.81
Arterial hypertension, % 72.4 71.6 0.87
Diabetes mellitus, % 51.3 32.2 0.002
Dyslipidaemia, % 51.9 43.9 0.22
Ischaemic CHD, % 16.9 11.4 0.18
Symptomatic PAD, % 18.2 7.6 0.005
Treatment before index stroke
Antiplatelet agents, % 29.5 24.7 0.39
Statins, % 33.3 26.8 0.49
Antihypertensive, % 61.5 60.4 0.62
Hypoglycaemics, % 41.0 25.4 0.01
Treatment at discharge
Antiplatelet agents 100 99.3 0.46
Statins 70.0 71.8 0.84
Antihypertensive drugs 75.6 72.8 0.65





Small vessel disease 18.4 21.0
Cryptogenic 10.5 20.3
mRankin <2 at discharge 41.0 57.9 0.08
mRankin ≤2 at 1 year 39.0 70.3 <0.0001
CHD: cardiac heart disease. PAD: peripheral artery disease.
P-value (log-rank test).
Table 2 Atherosclerotic marker factors associated with
new vascular events at one-year follow-up
Primary end-point
Yes (n = 78) No (n = 485) p
PAD <0.0001
No (ABI >0.90) 44.2 70.7




ICA Stenosis >50% 29.9 18.1 0.01
Vascular disease <0.0001
Normal ABI and ICA <50% 38.2 60.9
Normal ABI and ICA >50% 6.6 10.0










Isolated plaque 17.3 17.5
Multiple plaques 62.7 54.1
Echogenicity of plaques 0.35
Type I (uniform anechoic) 12.1 13.4
Type II (mainly hypoechoic) 15.5 16.4
Type III (mainly hyperechoic) 19.0 24.7
Type IV (uniform iso- or
hyperechoic)
51.7 39.3
Type V (calcified) 1.7 6.3
Plaques surface 0.19
Smooth and even 61.3 72.8
Uneven 37.1 25.8
Ulcerated 1.6 1.4
IMT mm (mean, SD) 0.94 (0.46) 0.91 (0.38) 0.57
Microalbuminuria 18.2 22.4 0.52
All values are percentages unless otherwise stated.
ABI: ankle brachial index. ICA: internal carotid stenosis (either ipsi or contralateral
to index stroke). IMT: intima-media thickness. PAD: peripheral artery disease.
p-value (Log-Rank test), apart from IMT (t-Student).
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tic markers of vascular events. The PATHOS and
SCALA studies [11,12] reported high prevalence of low
ABI among patients with acute ischaemic stroke or TIA.
Tsivgoulis et al. [13] identify ABI <0.9 as an independent
risk factor for recurrent stroke in patients with acute
cerebral ischaemia. Similarly, Busch et al. [14], Sen et al.
[15], and Purroy et al. [16] reported an independent
positive, adjusted association between asymptomatic
Table 3 Cox hazard ratios of primary outcome at
one-year follow-up
HR 95% CI p
Age 1.03 0.99-1.06 0.088
Sex 0.50 0.26-0.95 0.035
BMI 1.08 1.02-1.14 0.007
Systolic blood pressure 1.01 1.00-1.02 0.006
History of diabetes mellitus 2.05 1.22-3.45 0.007
mRankin scale at discharge ≥2 1.32 0.78-2.27 0.294
IMT 0.98 0.91-1.05 0.680
Vascular disease
Normal ABI and ICA >50% 1.38 0.52-3.69 0.551
ABI <0.9 and ICA <50% 1.64 0.81-3.30 0.160
Symptomatic PAD and ICA <50% 2.76 1.10-6.95 0.030
ABI <0.9 and ICA >50% 4.52 2.14-9.53 <0.001
Symptomatic PAD and ICA >50% 4.72 1.75-12.70 0.002
Sex (0 =men, 1 = women), history of diabetes (0 = No, 1 = Yes) and mRankin
scale at discharge ≥2 (0 = No, 1 = Yes) were included as categorical variables.
Reference category of vascular disease: normal ABI and CS <50%. BMI: body
mass index. ICA: internal carotid stenosis. IMT: intima-media thickness (by 0.1
units). PAD: peripheral artery disease. ABI: ankle brachial index.
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TIA, myocardial infarction, and death among patients
with previous stroke. Two studies, both conducted in
consecutive patients with a first ischaemic stroke of any
aetiopathogenic stroke subtype using the TOAST cri-
teria, have demonstrated the prognostic impact of IMT
in predicting stroke recurrence [17,18].
To the best of our knowledge, the ARTICO study is the
first study to analyse the adjusted potential predictive cap-
acity of ABI together with additional markers of athero-
thrombotic disease as predictors of new vascular events in
this particular group of patients where preventative treat-
ment is almost identical. Non-cardioembolic stroke ac-
counts for 60-70% of all ischaemic strokes in patients
older than 60 years with the risk of recurrence being as
high as 5-8% annually and up to 20-40% in the five years
after stroke in spite of correct preventive treatment being
followed [19].
One third of our non-cardioembolic stroke population
had a pathological ABI, which was more frequently asymp-
tomatic. This is a significantly higher prevalence than the
8.5-19% found in population studies [26] although in the
same range as recent studies in similar populations of
patients suffering from previous non-cardioembolic
stroke [44,45].
In the general population, an ABI ≤0.9 has been asso-
ciated with a higher number of atheromatous plaques,
higher IMT [46,47] and greater prevalence of ICA sten-
osis >70% [48,49]. In the previously cited studies in
stroke patients, an ABI ≤0.9 has been associated with a
higher risk of new vascular events [11-16]. The ARTICOstudy found a similar association in bivariate analysis, re-
fined by adjusting for potential confounders. In the
ARTICO stroke population, symptomatic PAD, and par-
ticularly the association of both symptomatic PAD and
ABI ≤0.9 with ICA stenosis >50%, were independently
associated in the multivariate analysis with a 3.72 and
4.39 times increased risk of new vascular events. Such
an association was not found with other analysed ather-
othrombotic markers such as IMT, plaque characteristics
or microalbuminuria. The presence of isolated ICA sten-
osis >50% or asymptomatic PAD (ABI <0.9) was not as-
sociated with an increased risk of new vascular events
when compared with the whole population. Like previous
studies, symptomatic PAD is associated with an increased
risk of recurrence and, as shown by the ARTICO study,
this is even higher when associated to ICA stenosis
(Table 3).
Unlike previous population-based studies where ICA
stenosis did not seem to increase the risk of vascular
events when associated to low ABI [48], we find that low
ABI together with ICA stenosis >50% is associated with
a particularly high risk of new vascular events in patients
who have suffered a first non-cardioemblic stroke.
The main contribution made by ARTICO is that this
is the first study focused on analysing different athero-
sclerotic markers of stroke recurrence in a prospective
non-cardioembolic stroke population adjusting for rele-
vant confounders in a multivariate survival analysis.
The principal limitation is the relatively short one-year
follow-up. A further limitation is the lack of analyses for
the different markers and individual outcomes due to
the low number of outcome events as a result, at least in
part, of the intensive preventive treatment that patients
received in the routine practice in line with the recom-
mendations of the Spanish Neurological Society Stroke
Group [50] (e.g. 70% of patients received statins at dis-
charge, in spite of there only being a 50% prevalence of
hypercholesterolaemia). As patients were included pro-
spectively and shortly after stroke (9 [6-20] days), bias
due to early stroke or vascular event recurrence seems
unlikely. It might be argued that there is a lack of de-
tailed information about stroke severity in our study and
that the NIHSS may have a high predictive value in the
outcome. However, the objective of our study was to ana-
lyse stroke recurrence as well as other vascular events. The
mRankin scale was recorded to evaluate the degree of dis-
ability or dependence in the daily activities of patients. An-
other possible criticism is that a broader array of predictive
atherothrombotic markers should have been studied. We
selected microalbuminuria as the only renal function par-
ameter in our study not only due to the practical need to
limit the scale of the investigation but particularly because
it is a well-established marker of generalised vascular dys-
function and a predictor of poor outcome after ischaemic
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buminuria might promote the development of subclinical
atheromatosis or destabilise subclinical atherosclerosis, a
hypothesis that has recently been proposed as the cause of
cardiovascular clinical events. A final possible limitation is
that, in part due to the hypothesis-generating nature of the
study, no formal sample size estimation was performed. In
this respect it should be noted that we present one of the
most extensive series to be published.
Conclusions
Specific atherothrombotic markers were found to be
highly prevalent in a non-cardioembolic stroke popula-
tion. The associated increased risk was particularly high
in patients with both ICA stenosis plus either symptom-
atic or asymptomatic PAD. Both ABI and ICA should be
evaluated in all non-cardioembolic strokes to identify
those patients with the greatest risk of vascular recur-
rence who might benefit from future studies focused on
additional intervention in secondary prevention.
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